Old Blood Pressure Drug Shows Promise Against Huntington’s Disease Chorea
A phase 2b European trial found that SOM3355, a repurposed beta-blocker with a novel triple mechanism, significantly reduced chorea in ...
A phase 2b European trial found that SOM3355, a repurposed beta-blocker with a novel triple mechanism, significantly reduced chorea in ...
New research shows that the microRNA miR-196a clears toxic mutant huntingtin aggregates in Huntington's disease by suppressing Rad23b, a ubiquitin ...
The 4th Clinical Epigenetics International Conference in Naples highlighted rapid progress in epigenetic mechanisms, editing technologies, and therapies for cancer, ...
A 12-week pilot trial found that an eight-hour time-restricted eating window was feasible, well tolerated, and associated with favorable clinical ...
A 12-week pilot study found that time-restricted eating was feasible and well tolerated in 20 people with early-stage Huntington's disease, ...
A Swedish study confirms that the immune protein TNFRSF8 (sCD30) is halved in the cerebrospinal fluid of Huntington's disease gene ...
A new Nature Communications study shows that Huntington's disease damages brain arterioles in a barrier-type-selective pattern coupled to reactive astrogliosis, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine